CI has just crossed the September 30 earnings date noted in the prior preview, and the stock added 1.3% on the day to close at $275.26, a modest but meaningful contrast to the July quarter, when it shed nearly 6% in a single session after that print.
The lending market remains entirely relaxed, and that has not changed from the picture described three days ago. Availability is essentially unconstrained, with over 255 million shares available to borrow against a short position of roughly 6.3 million, an availability ratio so wide it is capped at 9,999% in the data. Cost to borrow has also eased sharply, dropping to 0.31% from a brief spike to 1.26% on Monday, the lowest close in weeks. Short interest at 2.4% of the free float is marginally lower on the day but has climbed about 15.8% over the past month, edging from around 5.4 million shares to the current level. That is a grind higher in short interest, not a sudden conviction bet. There is no meaningful squeeze pressure, no crowding, and no sign of urgency on either side of the lending market. Options positioning echoes the same calm: the put/call ratio at 0.53 is slightly below its 20-day average of 0.56, and well inside the year's defensive extremes. Derivatives traders are not hedging into the next catalyst.
The Street remains split in a way that has barely shifted since the July results triggered a wave of downgrades. After that print, Jefferies cut to Hold and Raymond James stepped down from Strong Buy to Outperform, both trimming targets into the $307 to $320 range. The neutral-to-positive cohort, including Barclays and Wells Fargo at Equal-Weight with targets around $307 to $310, are essentially flagging fair value at a discount to the current price. The bulls, led by names like Guggenheim at $361, Bernstein at $381, UBS at $400, and Morgan Stanley at Overweight, sit at a mean target of $341.83, implying roughly 24% upside from here. The stock trades at a PE of around 8.4 and an EV/EBITDA of 6.9, both of which have edged higher over the past week. The EV/EBIT factor scores in the 89th percentile, suggesting the market already recognises the valuation discount, yet the stock is not being re-rated. EPS momentum scores are soft, ranking in the low 40s on both 30-day and 90-day windows, and the forward EPS growth percentile has slipped to 31. The market appears to be paying for the discount but not yet for the growth.
The fundamental debate that drives that stubborn discount has not resolved. Bulls anchor their case on Evernorth's specialty and pharmacy benefits scale, the $2,000 per engaged member annual saving the company's AI risk model is generating, and a healthcare medical loss ratio that improved in Q1. They also point to the Centene pharmacy benefit win and a mix shift away from lower-margin government exchange business. Bears counter that PBM margin erosion is structural, not transitory, that a rise in US unemployment would erode commercial membership, and that the $150 million of PBM headwinds flagged for this year may not fully dissipate. The July quarter's 5.9% single-day decline followed by a further 7.2% five-day drawdown shows the market's patience with execution misses is limited. With the next quarterly print now set for October 30, just 30 days away, management will need to demonstrate the PBM pressure is genuinely decelerating.
Retail attention is an outlier worth noting. The Wikipedia and ORTEX page-view signal scored a z-score of 2.0 as of September 22, well above the stock's own 90-day history. That spike likely reflects the earnings-date uncertainty and recent analyst activity rather than any new fundamental signal, but it does indicate the stock is drawing broader attention at a moment when the institutional view remains divided.
Vanguard Capital Management holds 7.1% of shares and added 153,000 shares in the most recently reported period. Norges Bank added 166,860 shares as of June 30. The activist register carries no 13D filers. Insider activity has been limited to planned sales under 10b5-1 programmes, most visibly from Nicole Jones, who sold a net $5.4 million in August through pre-arranged trades. Chairman and CEO David Cordani's last disclosed transaction was a May option exercise under a 10b5-1 plan, with no open-market buying on record in the window. Planned sales carry limited informational weight, but the absence of discretionary buying from C-suite names at these prices is worth noting.
The next focal point is the October 30 Q3 print, where the central question is whether PBM headwinds are tracked as decelerating in the data or whether the bear case on margin erosion starts to find more confirmation.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
